

Ekaterina Yu Chelysheva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/680812/publications.pdf>

Version: 2024-02-01

22
papers

272
citations

1163117

8
h-index

888059

17
g-index

23
all docs

23
docs citations

23
times ranked

287
citing authors

#	ARTICLE	IF	CITATIONS
1	Russian Prospective Non-Randomized Clinical Study on Dose Reduction of Tyrosine Kinase Inhibitors with Subsequent Complete Therapy Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response (READIT-2020): Background, Aim, Main Objectives, Design, and Expected Results. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2022, 15, 54-61.	0.4	0
2	Factors for Sustaining Molecular Remission after Discontinuation of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia: Results of Non-Randomized Prospective Clinical Trial. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2021, 14, 1-12.	0.4	3
3	Opportunities of Chronic Myeloid Leukemia Treatment with Reduced Doses of Tyrosine Kinase Inhibitors. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2021, 14, 118-128.	0.4	1
4	Biological Mechanisms of Sustaining Deep Molecular Response in Chronic Myeloid Leukemia Upon Withdrawal of Tyrosine Kinase Inhibitors. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2021, 14, 427-435.	0.4	0
5	Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096612.	2.5	29
6	A prospective study of the monitoring of patients with chronic myeloid leukemia upon withdrawal of tyrosine kinase inhibitor therapy. <i>Gematologiya I Transfuziologiya</i> , 2020, 65, 370-385.	0.6	3
7	Risks and challenges of CML management during pregnancy: Looking for a balanced decision. <i>European Journal of Haematology</i> , 2019, 102, 378-379.	2.2	10
8	Exome, transcriptome and miRNA analysis donâ€™t reveal any molecular markers of TKI efficacy in primary CML patients. <i>BMC Medical Genomics</i> , 2019, 12, 37.	1.5	4
9	Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database. <i>Blood</i> , 2019, 134, 498-498.	1.4	11
10	TREATMENT OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ACCORDING TO THE RUSSIAN PART OF THE EUTOS POPULATION-BASED STUDY. <i>Gematologiya I Transfuziologiya</i> , 2019, 64, 106-121.	0.6	5
11	Treatment-free remission in patients with chronic myeloid leukemia: literature review. <i>Oncogematologiya</i> , 2019, 14, 12-22.	0.3	3
12	CHANGES IN STROMAL PROGENITOR CELLS DERIVED FROM BONE MARROW IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKAEMIA AT THE ONSET OF THE DISEASE AND DURING TREATMENT. <i>Gematologiya I Transfuziologiya</i> , 2019, 64, 424-435.	0.6	1
13	Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation. <i>Leukemia and Lymphoma</i> , 2018, 59, 2512-2515.	1.3	1
14	Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. <i>Leukemia and Lymphoma</i> , 2018, 59, 733-738.	1.3	29
15	Treatment of Patients with Chronic Myeloid Leukemia During Pregnancy According to Scheme Considering the Leukemic Burden and Term of Pregnancy (the LRT Scheme). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S227-S228.	0.4	2
16	Chronic Myeloid Leukemia Diagnosed during Pregnancy: Therapy, Outcomes and Follow-up. <i>Blood</i> , 2018, 132, 4255-4255.	1.4	6
17	Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy. <i>Blood</i> , 2018, 132, 4254-4254.	1.4	6
18	Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017, 10, 2018027.	1.3	21

#	ARTICLE	IF	CITATIONS
19	GROUP OF AUTHORS UNDER THE SUPERVISION OF ACADEMICIAN VG SAVCHENKO. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2017, 10, 294-316.	0.4	19
20	Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients. Leukemia and Lymphoma, 2016, 57, 1669-1676.	1.3	16
21	The impact of dasatinib on pregnancy outcomes. American Journal of Hematology, 2015, 90, 1111-1115.	4.1	98
22	Introduction of a Treatment Approach for Chronic Myeloid Leukemia and Pregnancy Considering Leukemic Burden and Pregnancy Terms. Blood, 2015, 126, 5144-5144.	1.4	3